Corticosteroid Tapering Guidelines
Introduction to Tapering
- A gradual tapering schedule should be followed when discontinuing prednisone to prevent adrenal insufficiency, especially after significant corticosteroid exposure, as recommended by the American College of Rheumatology 1
- The dosing pattern of prednisone can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, necessitating a structured approach to withdrawal, with the American College of Rheumatology suggesting a tapering schedule 1
Tapering Schedule
- The tapering schedule should start with reducing the dose from 10mg to 7.5mg daily for one month, then to 5mg daily for one month, followed by 2.5mg daily for one month, and finally 2.5mg every other day for 2 weeks before stopping, as suggested by the American College of Rheumatology 1
- The dose should be reduced by 2.5mg each month as tolerated, with monitoring for signs of disease flare or withdrawal symptoms, and aiming for a low-dose prednisone of ≤10 mg/day, as recommended by the American Association for the Study of Liver Diseases 2
Monitoring and Adjustments
- During tapering, monitor for signs of disease flare or withdrawal symptoms, such as fatigue, weakness, dizziness, nausea, or low blood pressure, and adjust the tapering schedule accordingly, as recommended by the American College of Rheumatology 1
- If symptoms worsen during tapering, temporarily reinstate the previous effective dose before attempting a slower taper, and consider increasing azathioprine to 2 mg/kg daily while gradually withdrawing prednisone, as suggested by the American Association for the Study of Liver Diseases 2
Special Considerations
- HPA axis suppression should be anticipated in anyone receiving more than 7.5mg of prednisolone equivalent daily for more than 3 weeks, and the current regimen of 10mg for 20 days/month puts patients at risk for adrenal insufficiency if stopped abruptly, according to the American College of Rheumatology 1
- During periods of significant physical stress, such as surgery, severe illness, or trauma, patients may temporarily need increased doses of prednisone, and for major stress, switching to intravenous hydrocortisone might be necessary, as suggested by the American College of Rheumatology 1
- Budesonide may provide similar efficacy with reduced systemic side effects due to first-pass metabolism, but should not be used in patients with cirrhosis or portal hypertension, as noted by the American Association for the Study of Liver Diseases 3, 2
Withdrawal Symptoms and Complications
- Common withdrawal symptoms include joint pain and stiffness, fatigue, weakness, headache, and nausea, and if these occur, the tapering process should be slowed down, as recommended by the American College of Rheumatology 1
- Never stopping prednisone abruptly is crucial, as it can lead to acute adrenal crisis, which can be life-threatening, according to the American College of Rheumatology 1
- Regular monitoring of blood glucose and blood pressure is recommended, as well as implementing lifestyle interventions for metabolic syndrome, with the American Association for the Study of Liver Diseases emphasizing the importance of metabolic monitoring 3
- Monitor bone density regularly and consider bisphosphonates for high-risk patients, as suggested by the American Association for the Study of Liver Diseases 3
- Be vigilant for signs of infection, particularly with doses >10 mg/day, and consider prophylaxis for opportunistic infections in high-risk patients, according to the American Association for the Study of Liver Diseases 3
Maintenance and Follow-up
- Check laboratory values every 3-4 months during stable maintenance and monitor for side effects at each visit, with particular attention to blood pressure, weight changes, skin changes, visual changes, mood alterations, and bone health, as recommended by the American Association for the Study of Liver Diseases 3
- The indefinite low-dose prednisone strategy (maintaining ≤10 mg/day) has shown satisfactory outcomes with minimal new side effects over observation periods up to 149 months, according to the American Association for the Study of Liver Diseases 2